Invited Commentary: Every Good Randomization Deserves Observation

American Journal of Epidemiology

Volumn 182, Issue 10, 2015, Pages 857-860

  Westreich, Daniel ^a   Edwards, Jessie K ^a  

^a University of North Carolina at Chapel Hill   (United States)

Author keywords

adherence; causal inference; external validity; generalizability; HIV; pre exposure prophylaxis; randomized trials; transportability

Indexed keywords

CLINICAL OBSERVATION; EXTERNAL VALIDITY; HELP SEEKING BEHAVIOR; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INTENTION TO TREAT ANALYSIS; INTERNAL VALIDITY; KENYA; NOTE; PATIENT COMPLIANCE; PRE-EXPOSURE PROPHYLAXIS; RANDOMIZED CONTROLLED TRIAL (TOPIC); RISK FACTOR; UGANDA; UNITED STATES; FEMALE; HIV INFECTIONS; MALE; MEDICATION COMPLIANCE; METHODOLOGY; PROCEDURES; STATISTICS AND NUMERICAL DATA;

HUMAN IMMUNODEFICIENCY VIRUS;

ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT; EMTRICITABINE PLUS TENOFOVIR DISOPROXIL;

ANTI-HIV AGENTS; EMTRICITABINE, TENOFOVIR DISOPROXIL FUMARATE DRUG COMBINATION; FEMALE; HIV INFECTIONS; HUMANS; MALE; MEDICATION ADHERENCE; PRE-EXPOSURE PROPHYLAXIS; RESEARCH DESIGN;

EID: 84947598877     PISSN: 00029262     EISSN: 14766256     Source Type: Journal    
DOI: 10.1093/aje/kwv200     Document Type: Note

References (25)

1. Grant RM, Lama JR, Anderson PL, et al. Preexposure chemoprophylaxis for HIV prevention in men who have sex with men. N Engl J Med. 2010;363(27):2587-2599.
2. Baeten JM, Donnell D, Ndase P, et al. Antiretroviral prophylaxis for HIV prevention in heterosexual men and women. N Engl J Med. 2012;367(5):399-410.
3. Van Damme L, Corneli A, Ahmed K, et al. Preexposure prophylaxis for HIV infection among African women. N Engl J Med. 2012;367(5):411-422.
4. Thigpen MC, Kebaabetswe PM, Paxton LA, et al. Antiretroviral preexposure prophylaxis for heterosexual HIV transmission in Botswana. N Engl J Med. 2012;367(5):423-434.
5. Choopanya K, Martin M, Suntharasamai P, et al. Antiretroviral prophylaxis for HIV infection in injecting drug users in Bangkok, Thailand (the Bangkok Tenofovir Study): a randomised, double-blind, placebo-controlled phase 3 trial. Lancet. 2013;381(9883):2083-2090.
6. Marrazzo JM, Ramjee G, Richardson BA, et al. Tenofovir-based preexposure prophylaxis for HIV infection among African women. N Engl J Med. 2015;372(6):509-518.
7. Osterberg L, Blaschke T. Adherence to medication. N Engl J Med. 2005;353(5):487-497.
8. Murnane PM, Brown ER, Donnell D, et al. Estimating efficacy in a randomized trial with product nonadherence: application of multiple methods to a trial of preexposure prophylaxis for HIV prevention. Am J Epidemiol. 2015;182(10):848-856.
9. Frangakis CE, Rubin DB. Principal stratification in causal inference. Biometrics. 2002;58(1):21-29.
10. Robins JM, Finkelstein DM. Correcting for noncompliance and dependent censoring in an AIDS clinical trial with inverse probability of censoring weighted (IPCW) log-rank tests. Biometrics. 2000;56(3):779-788.
11. Cain LE, Cole SR. Inverse probability-of-censoring weights for the correction of time-varying noncompliance in the effect of randomized highly active antiretroviral therapy on incident AIDS or death. Stat Med. 2009;28(12):1725-1738.
12. Del Re AC, Maisel NC, Blodgett JC, et al. Intention-to-treat analyses and missing data approaches in pharmacotherapy trials for alcohol use disorders. BMJ Open. 2013;3(11):e003464.
13. Armijo-Olivo S, Warren S, Magee DJ. Intention to treat analysis, compliance, drop-outs and how to deal with missing data in clinical research: a review. Phys Ther Rev. 2009;14(1):36-49.
14. Hernán MA, Hernández-Díaz S. Beyond the intention-to-treat in comparative effectiveness research. Clin Trials. 2012;9(1):48-55.
15. Hernán MA, VanderWeele TJ. Compound treatments and transportability of causal inference. Epidemiology. 2011;22(3):368-377.
16. Bareinboim E, Pearl J. A general algorithm for deciding transportability of experimental results. J Causal Inference. 2013;1(1):107-134.
17. Bareinboim E, Lee S, Honavar V, et al. Transportability from multiple environments with limited experiments. Adv Neural Inf Process Syst. 2013;26:136-144.
18. Bareinboim E, Pearl J. Transportability from multiple environments with limited experiments: completeness results. Adv Neural Inf Process Syst. 2014;27:280-288.
19. Hoggatt KJ, Greenland S. Commentary: extending organizational schema for causal effects. Epidemiology. 2014;25(1):98-102.
20. Cole SR, Stuart EA. Generalizing evidence from randomized clinical trials to target populations: the ACTG 320 Trial. Am J Epidemiol. 2010;172(1):107-115.
21. Petersen ML. Compound treatments, transportability, and the structural causal model: the power and simplicity of causal graphs. Epidemiology. 2011;22(3):378-381.
22. Daniel RM, Kenward MG, Cousens SN, et al. Using causal diagrams to guide analysis in missing data problems. Stat Methods Med Res. 2012;21(3):243-256.
23. Frangakis C. The calibration of treatment effects from clinical trials to target populations. Clin Trials. 2009;6(2):136-140.
24. Westreich D, Cole SR, Young JG, et al. The parametric g-formula to estimate the effect of highly active antiretroviral therapy on incident AIDS or death. Stat Med. 2012;31(18):2000-2009.
25. Westreich D. From exposures to population interventions: pregnancy and response to HIV therapy. Am J Epidemiol. 2014;179(7):797-806.